- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00891345
Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy (ALECSAT)
A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering ALECSAT to Prostate Cancer Patients - a First Dose in Man Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective open phase I study to investigate the safety and tolerability of administration of a single dose of a cell based medicinal product (CBMP) ALECSAT.
ALECSAT is an autologous CBMP that is made from the patient's own blood cells. ALECSAT contains a large amount of tumour specific cytotoxic Lymphocytes (CTL) and Natural Killer (NK) cells that are isolated activated and amplified in number.
The CBMP is given as a slow i. v. injection to patients with prostate cancer. The patients are in the late stage of the disease where they have received hormone treatment but their disease is progressing.
The primary objective of the study is to observe if any side effects or tolerability issues occur as a consequence of the cell administration, secondarily it will be observed if any positive anti tumour effect may be observed. The study has the purpose to investigate whether treatment with ALECSAT in any way is toxic.
Trial Design: The study is an open, prospective phase I safety study of ALECSAT in prostate cancer patients.
A group consisting of 6 patients will be treated with ALECSAT according to the protocol. Then an interim analysis will be done. If there are no signs of significant toxicity related to the treatment, the study will continue with 8 more patients that will be included and treated with ALECSAT according to the phase I protocol. Thus this study will include a total of 14 patients.
The patients will after a single administration of ALECSAT be hospitalised for 3 days and will furthermore be followed closely for 7 weeks by 5 planned study visits, by the investigators at Urologisk Klinik at Fredrikssund Hospital.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Frederikssund, Denmark, DK-3600
- Urological Clinic, Frederikssunds Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hormone-refractory prostate cancer patients
- Three consecutive rises of PSA min. 2 weeks apart, resulting in at least two 50% increases over the PSA nadir.
- Antiandrogen withdrawal for at least 4 weeks, or
- PSA progression despite secondary hormonal manipulations, or
- Progression of osseous or soft tissue lesions.
- Serum castration levels of testosterone.
- Be capable of understanding the information and giving informed consent.
- Expected survival time (life expectancy) of over 4 months.
- Adequate performance status (WHO / ECOG Performance status score 2 or less).
Exclusion Criteria:
- Patients with a low blood count (haemoglobin < 6.0 mmol/l).
- Patients with lymphocyte-numbers below 0.8.
- Patients known to be HIV and/or hepatitis positive i.e. patients positive in tests for anti-HIV-1/2; HBsAg, anti-HBc and Anti-HCV.
- Patients known to have syphilis i.e. being positive in a Treponema Pallidum test.
- Patients with uncontrolled serious bacterial, viral, fungal or parasitic infection.
- Patients must have no clinically significant autoimmune disorders or conditions of immune suppression.
- Patients that have been treated with corticosteroids (steroid hormones) or bisphosphonates or have been in chemotherapy or radiation treatment one month prior to inclusion in the clinical trial.
- Fertile patients.
- Patients that have received blood transfusions within 48 hours prior to donation of blood for ALECSAT production.
- Patients must not have been included in other clinical trials 6 weeks prior to inclusion in the trial or be enrolled in other clinical trials during the ALECSAT clinical trial.
- Any medical condition that will render participation in the study risky or, according to the investigator in charge, will make the assessment of side-effects difficult.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary endpoint is to show safety and tolerability for the administration of ALECSAT to enable further clinical development of the ALECSAT therapy.
Time Frame: Within 7 weeks
|
Within 7 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The secondary endpoint for this study is to establish if any indications of a positive therapeutic effect on the prostate cancer may be observed.
Time Frame: Within 7 weeks
|
Within 7 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hans-Henrik Meyhoff, MD, Urologisk Klinik, Frederikssund Hospital, Frederikssundsvej 30, 3600 Frederikssund
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CV001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hormone-refractory Prostate Cancer
-
University of California, IrvineBristol-Myers SquibbCompletedRecurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate CancerUnited States
-
DendreonCompletedHormone Refractory Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer MetastaticUnited States
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHormone Refractory Prostate Cancer | Metastatic Prostate CarcinomaChina
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Hormone-refractory Prostate CancerUnited States
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedProstate Cancer | Hormone Refractory Prostate CancerUnited States
-
Spanish Oncology Genito-Urinary GroupAstellas Pharma Inc; Apices Soluciones S.L.CompletedHormone-refractory Prostate CancerSpain
-
Peking UniversityWithdrawnHormone Refractory Prostate CancerChina
-
Tianjin Medical University Cancer Institute and...UnknownHormone Refractory Prostate CancerChina
-
CytoVac A/SCompletedHormone-refractory Prostate CancerDenmark
-
British Columbia Cancer AgencyCompletedHormone Refractory Prostate CancerCanada
Clinical Trials on ALECSAT
-
CytoVac A/SCompletedHormone-refractory Prostate CancerDenmark
-
CytoVac A/SCompleted
-
CytoVac A/SCompleted
-
Henrik DitzelNational Board of Health, Denmark; CytoVac A/SRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast CancerDenmark
-
CytoVac A/STerminatedGlioblastoma MultiformeDenmark
-
CytoVac A/SCompleted